Results of the SEL-I-METRY Phase II Trial on Resensitization of Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine Therapy
Jonathan Wadsley(Weston Park Cancer Centre), Sarah Brown(University of Leeds), J. L. Marshall(Mitchell Institute), Matthew Griffin(Nottingham University Hospitals NHS Trust), A. Pascoe(Nottingham University Hospitals NHS Trust), Matthew Beasley(University Hospitals Bristol NHS Foundation Trust), Kate Newbold(Royal Marsden NHS Foundation Trust), Amy Beth Coulson(University of Leeds), Gemma Ainsworth(University of Leeds), Andrew Weaver(University of Victoria), J. Taprogge(Royal Marsden Hospital), Yong Du(Royal Marsden Hospital), Glenn Flux(Royal Marsden NHS Foundation Trust), Jayne Swain(University of Leeds), Kate Garcez(The Christie NHS Foundation Trust), Katie Wood(Royal Surrey County Hospital), Laura Moss(Velindre Cancer Centre), Kate Farnell(British Thyroid Foundation), Helen Howard(University of Leeds)
Cited by 19
Related Papers
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
|The Lancet Oncology|2019|1.2k
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
|The Lancet Oncology|2013|728
2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
|Thyroid|2021|699